Bristol-Myers Squibb CEO and key executive team

• Giovanni Caforio

  Chairman of the Board and Chief Executive Officer
• Jeff Staiger

  Vice President, Cardiovascular, Fibrosis, Immunology, Neuroscience Business Development
• Elizabeth Mily

  Executive Vice President Strategy and Business Development
• Rupert Vessey

  Executive Vice President and President, Research and Early Development
• Brian Heaphy

  Vice President, Corporate Development
• Sandra Leung

  Executive Vice President, General Counsel
• Nadim Ahmed

  Executive Vice President and President, Hematology
• Chris Boerner

  Executive Vice President, Chief Commercialization Officer
• David Elkins

  Executive Vice President and Chief Financial Officer
• Samit Hirawat

  Executive Vice President, Chief Medical Officer, Global Drug Development
• Severine Lacourt

  Chief of Staff to the Chief Executive Officer
• Ann M. Powell

  Executive Vice President, Chief Human Resources Officer
• Lou Schmukler

  Executive Vice President and President, Global Product Development & Supply
• Paul von Autenried

  Executive Vice President, Chief Information Officer
• Kathryn Metcalfe

  Executive Vice President
• Elizabeth A. Mily

  Executive Vice President, Strategy & Business Development
• Ho Sung Cho

  Senior Vice President, Discovery Biotherapeutics, San Diego, CA
• Robert Merriman

  Executive Director, Corporate Development Transactions
• Adam Dubow

  Senior Vice President, Chief Compliance and Ethics Officer
• Joseph E. Eid

  Senior Vice President and Head of Global Medical Affairs
• Kristen M. Hege

  Senior Vice President, Early Clinical Development, Oncology/Hematology and Cell Therapy
• Mark Rolfe

  Senior Vice President, Oncogenesis Thematic Research Center
• Sunil Patel

  Senior Director, Divestitures
• Daniel O'Connell

  Executive Director, Equity and Venture Capital
• Beatrice Anduze-Faris

  Vice President, Global Clinical Compliance & Continuous Improvement (GCC&CI), Global Development Operations
• Sharon Cload

  Vice President, Molecular Discovery Technologies
• Emma Lees

  Vice President, & Site Head of R&D, Oncology Discovery
• Binodh Desilva

  Vice President, Lead, Discovery and Optimization, Small Molecule Drug Discovery
• Melissa Harris

  Vice President and Head of Fibrosis Development
• Tim Power

  Vice President, Investor Relations
• Myrtle Davis

  Executive Director, Discovery Toxicology, Central New Jersey
• Stephen O'Keefe

  Senior Director, Business Development, Hematology Search & Evaluation
• Jie D'Elia

  Vice President, Business Development, Hematology, Cell Therapy and China
• Ken Lamontagne

  Senior Director, Business Development, Cell Therapy Search & Evaluation
• David Gordon

  Vice President, Cardiovascular and Fibrosis Discovery Biology, Central New Jersey
• Jennifer Schwartz

  Executive Director, Business Development, Hematology & Cell Therapy Transactions
• Konstantina Katcheves

  Vice President, Innovative Technologies Business Development
• Michaela Bowden

  Director, Translational Biology
• Evan Janovitz

  Director of Pathology, Discovery Toxicology
• Michael May

  Countrywide Medical Director, Germany, Global Medical
• Joseph Szustakowski

  Executive Director, Translational Bioinformatics
• Josh Hansen

  Director, Chemistry
• Michael Cucolo

  Executive Director, Business Development, Research Enabling Transactions
• Fang Zhang

  Executive Director, China Business Development
• Paula A. Price

  Director
• Jay Foust

  Executive Director, Business Development, Translational Medicine
• Catalina Vargas

  Chief of Staff to the Chief Executive Officer
• Saumya Pant

  Director, Clinical Genomics & Genetics, Central New Jersey
• Michael McInerney

  Senior Director, Business Development, Digital Health
• Robert Plenge

  Senior Vice President and Head, Immunology, Cardiovascular and Fibrosis Thematic Research Center

Source: bms.com, news.bms.com, bms.com, bms.com, bms.com